Lichen Plano-Pilaris

1

Review clinical trials related to Lichen Plano-Pilaris. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.

Participants needed: 10
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: The Skin Center Dermatology GroupUpdated: Feb 10, 2026Locations: 1
Eligibility criteria

Age ≥18 years. [+5]

Other forms of alopecia that may interfere with study assessments. [+13]